Results 141 to 150 of about 23,995,846 (308)
KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer
Molecular Oncology, EarlyView.Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan +16 more
wiley +1 more source
Trend-resistant and cost-efficient cross-over designs for mixed models. [PDF]
A mixed model approach is used to construct optimal cross-over designs. In a cross-over experiment the same subject is tested at different points in time.
Tack, L, Vandebroek, Martina
core
A bivariate mixed model approach for the analysis of plant survival data
, 2013 Disease resistance is often measured as plant survival, which involves taking multiple counts of plants before and after disease incidence. Often, survival data are analyzed by forming a single derived variable, namely final counts expressed as a ...
Beeck, C. +10 more
core +1 more source
Molecular Oncology, EarlyView.RNA profiling of circulating extracellular vesicles (EVs) from blood samples of men undergoing prostate biopsy identifies transcripts associated with clinically significant prostate cancer. Integrative analysis with public tumor datasets links EV‐derived gene signatures to tumor stage and progression‐free survival, highlighting CASP3, XRCC2, and RIT1 ...
Stefan Werner +14 more
wiley +1 more source
Lack-of-fit tests in semiparametric mixed models. [PDF]
In this paper we obtain the asymptotic distribution of restricted likelihood ratio tests in mixed linear models with a fixed and finite number of random effects.
Claeskens, Gerda +2 more
core
Molecular Oncology, EarlyView.This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska +13 more
wiley +1 more source
Molecular Oncology, EarlyView.Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura +19 more
wiley +1 more source
The Value of a Statistical Life: a Meta-Analysis with a Mixed Effects Regression Model [PDF]
The value of a statistical life (VSL) is a very controversial topic, but one which is essential to the optimization of governmental decisions. Indeed, our society faces any number of risks (health, transportation, work, etc.) and, as resources are ...
Georges Dionne +2 more
core
Molecular Oncology, EarlyView.We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober +16 more
wiley +1 more source
High resolution aerosol data from MODIS satellite for urban air quality studies
Open Geosciences, 2014 Chudnovsky A. +5 more
doaj +1 more source